Study shows efficacy of anti-VEGF therapy in myopic CNV
Based on positive outcomes from the RADIANCE trial, ranibizumab has recently been approved by European authorities as a treatment for patients with choroidal neovascularization (CNV) secondary to pathologic myopia, according to Sebastian Wolf MD.
“The trial data showed that ranibizumab provides rapid and superior improvement in visual acuity compared with the current licensed standard of care, photodynamic therapy with verteporfin after three months. There was an average 14-letter visual acuity gain in the first year with a median of two injections and more than 60 per cent of patients in the study did not need any further injections after six months,” said Dr Wolf.
Tags: intraocular pressure
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.